vTv Therapeutics Inc.
VTVT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641489
No open-market purchases or sales by vTv Therapeutics Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $60.5M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in vTv Therapeutics Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +2 vs. Q2 2024
- Shares held
- 542.3K
- +195.3K (+56.3%) vs. Q2 2024
- Total value
- $7.34M
- +$1.21M (+19.7%) vs. Q2 2024
- New holders
- 6
- 2 more added
- Sold out
- 4
- 1 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VTVT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $60.5M |
| Q1 2026 | 35 | $59.0M |
| Q4 2025 | 27 | $51.3M |
| Q3 2025 | 23 | $23.1M |
| Q2 2025 | 21 | $8.74M |
| Q1 2025 | 21 | $9.90M |
| Q4 2024 | 17 | $7.57M |
| Q3 2024 | 20 | $7.34M |
| Q2 2024 | 19 | $6.15M |
| Q1 2024 | 19 | $7.85M |
| Q4 2023 | 14 | $788.7K |
| Q3 2023 | 25 | $1.65M |
| Q2 2023 | 20 | $2.60M |
| Q1 2023 | 24 | $2.88M |
| Q4 2022 | 30 | $2.47M |
| Q3 2022 | 27 | $3.38M |
| Q2 2022 | 23 | $2.75M |
| Q1 2022 | 25 | $3.76M |
| Q4 2021 | 29 | $6.49M |
| Q3 2021 | 31 | $5.17M |
| Q2 2021 | 42 | $9.89M |
| Q1 2021 | 48 | $13.5M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding vTv Therapeutics Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 206,784 | $2.81M | 0.54% | 00.0% | Unchanged |
| FMR LLC | 178,200 | $2.40M | 0.00% | +178,200 | New |
| Baker Bros. Advisors LP | 97,314 | $1.32M | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 41,558 | $560.2K | 0.00% | +17,000+69.2% | Added |
| Geode Capital Management, LLC | 10,307 | $139.0K | 0.00% | +10,307 | New |
| BlackRock, Inc. | 4,750 | $64.4K | 0.00% | +4,750 | New |
| UBS Group AG | 866 | $11.7K | 0.00% | −3,314−79.3% | Reduced |
| Morgan Stanley | 840 | $11.4K | 0.00% | 00.0% | Unchanged |
| Planning Capital Management Corp | 625 | $8.48K | 0.01% | 00.0% | Unchanged |
| Royal Bank of Canada | 296 | $4.00K | 0.00% | +296 | New |
| Tower Research Capital LLC (TRC) | 269 | $3.65K | 0.00% | +269 | New |
| Advisor Group Holdings, Inc. | 178 | $2.41K | 0.00% | +8+4.7% | Added |
| Strengthening Families & Communities, LLC | 173 | $2.35K | 0.00% | 00.0% | Unchanged |
| Activest Wealth Management | 50 | $678 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 38 | $515 | 0.00% | 00.0% | Unchanged |
| Planned Solutions, Inc. | 25 | $339 | 0.00% | +25 | New |
| Cornerstone Planning Group LLC | 19 | $265 | 0.00% | 00.0% | Unchanged |
| Sunbelt Securities, Inc. | 15 | $203 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 9 | $121 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 8 | $109 | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 0 | $0 | 0.00% | −12,256−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Triad Wealth Partners, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |